Anaerobic infections and Clostridium difficile colitis emerging during antibacterial therapy.
Almost all cases of Clostridium difficile-related pseudomembranous colitis are related to antimicrobial therapy. Virtually all antibacterial agents have been implicated, notable exceptions being vancomycin and parenterally administered aminoglycosides. The most prominent causes of colitis are ampicillin, clindamycin and various cephalosporins. In general, this complication is related to suppression of indigenous flora and overgrowth of C. difficile. In the case of ampicillin, however, C. difficile is always susceptible. Beta-lactamase production by elements of the bowel flora leads to destruction of ampicillin and subsequently to increased counts of C. difficile and colitis. Much less well-appreciated, and much less studied, is overgrowth and subsequent infection by other types of anaerobic bacteria. Superinfection by anaerobes may follow the use of "intestinal antiseptics" such as oral neomycin; indeed, that is the rationale for the current practice in the U.S. of combining erythromycin or tetracycline with the oral aminoglycoside. Superinfection with anaerobes may also follow systemic administration of various antimicrobial compounds. Such superinfections may involve any site in the body, although sepsis and intraabdominal infection have been noted most commonly; all major types of anaerobes have been involved. A wide variety of antimicrobial compounds has been implicated in predisposing to anaerobic infection.
D000900:Anti-Bacterial Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001421:Bacteria, Anaerobic / Q000254:growth & development; D001424:Bacterial Infections / Q000209:etiology*; D003013:Clostridium / Q000254:growth & development; D004761:Enterocolitis, Pseudomembranous / Q000209:etiology*; D006801:Humans
D000900:Anti-Bacterial Agents